SGMT
What one share of Sagimet Biosciences holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate.
Sagimet Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.25 |
|---|---|
| Cash and investments | $4.85 |
| Book value | $4.82 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$165.20 | — | −$132.65 | — | −$1,010 |
| 2023 | $0.19 | −$2.66 | — | −$2.27 | — | — |
| 2024 | — | −$1.45 | — | −$1.35 | — | $4.97 |
| 2025 | — | −$1.58 | — | −$1.41 | — | $3.44 |